Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports

Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports

Abstract Background The outcomes of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) can improve with allogeneic hematopoietic stem cell transplantation (HSCT) during the first complete remission after treatment with a tyrosine kinase inhibitor (TKI) combined with chemothera...

Full description

Bibliographic Details
Main Authors: Junichiro Yuda, Nobuhiko Yamauchi, Ayumi Kuzume, Yong-Mei Guo, Nobue Sato, Yosuke Minami
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Journal of Medical Case Reports
Subjects:
Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Blinatumomab
Ponatinib
Tyrosine kinase inhibitor
BCR–ABL compound mutations
Online Access:https://doi.org/10.1186/s13256-021-02771-z

Internet

https://doi.org/10.1186/s13256-021-02771-z

Similar Items